CXCR4 and leukemia: Cells with higher surface CXCR4 upregulation also had greater differences between the Protective and Reversal Index, suggesting that plerixafor diminishes stromal protection more effectively in leukemias that highly upregulate surface CXCR4 in response to chemotherapy.